EndoEvolution today claimed a win in its patent battle with JNJ subsidiary Ethicon over automated suturing technology.
Raynham, Mass.-based EndoEvolution said the U.S. Patent & Trademark Office’s Patent Trial & Appeal Board denied Ethicon’s bid for an inter partes review of an EndoEvolution patent.
Ethicon had challenged 30 claims in the EndoEvolution patent, the latter company said.
“In its written decision, however, the PTAB determined that Ethicon failed to establish that there is a reasonable likelihood of showing that any of the challenged claims are unpatentable, and that therefore the petition was denied,” EndoEvolution said.
“We are pleased with the PTAB’s confirmation of the novelty of our technology which continues to demonstrate clinical value across a broad range of minimally invasive surgical procedures,” president & CEO Ron Rudowsky said in prepared remarks.